185 reports of this reaction
6.9% of all ARGATROBAN reports
#1 most reported adverse reaction
HEPARIN INDUCED THROMBOCYTOPENIA is the #1 most commonly reported adverse reaction for ARGATROBAN, manufactured by Accord Healthcare Inc.. There are 185 FDA adverse event reports linking ARGATROBAN to HEPARIN INDUCED THROMBOCYTOPENIA. This represents approximately 6.9% of all 2,692 adverse event reports for this drug.
Patients taking ARGATROBAN who experience heparin induced thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPARIN INDUCED THROMBOCYTOPENIA is moderately reported among ARGATROBAN users, representing a notable but not dominant share of adverse events.
In addition to heparin induced thrombocytopenia, the following adverse reactions have been reported for ARGATROBAN:
The following drugs have also been linked to heparin induced thrombocytopenia in FDA adverse event reports:
HEPARIN INDUCED THROMBOCYTOPENIA has been reported as an adverse event in 185 FDA reports for ARGATROBAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPARIN INDUCED THROMBOCYTOPENIA accounts for approximately 6.9% of all adverse event reports for ARGATROBAN, making it one of the most commonly reported side effect.
If you experience heparin induced thrombocytopenia while taking ARGATROBAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.